5,980 Shares of Invesco Biotechnology & Genome ETF $PBE Purchased by Investment House LLC

Investment House LLC bought a new position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,980 shares of the company’s stock, valued at approximately $582,000.

A number of other large investors have also added to or reduced their stakes in the company. YHB Investment Advisors Inc. purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter valued at about $2,169,000. Royal Bank of Canada boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 25.9% in the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock valued at $4,698,000 after buying an additional 12,215 shares in the last quarter. Newman Dignan & Sheerar Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $912,000. Dynamic Advisor Solutions LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth approximately $484,000. Finally, MinichMacGregor Wealth Management LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 3rd quarter worth approximately $372,000.

Invesco Biotechnology & Genome ETF Stock Down 0.7%

NYSEARCA PBE opened at $98.72 on Friday. The firm has a market cap of $428.44 million, a PE ratio of 20.44 and a beta of 0.70. The company has a 50 day moving average price of $96.49 and a 200 day moving average price of $89.48. Invesco Biotechnology & Genome ETF has a 52 week low of $72.27 and a 52 week high of $99.99.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.